Table 3.

Influence of the window size on outcomes for change in PEF% p by treatment group

Window Size	Treatment group (n)	PEF% p (baseline)1	Change from baseline to week 522	Treatment Difference at week 522	Treatment Difference Overall 2 ,3
2 weeks	Idebenone (n = 31)	53.1 (12.3)	–1.95 (–6.56, 2.66)	7.73 (1.30, 14.16) p = 0.0192	5.19 (0.80, 9.58) p = 0.0212
	Placebo (n = 31)	52.5 (14.9)	–9.68 (–14.15, –5.20)
3 weeks	Idebenone (n = 31)	53.1 (12.3)	–1.77 (–6.38, 2.84)	7.24 (0.82, 13.66) p = 0.0277	4.72 (0.45, 8.99) p = 0.0310
(main analysis)	Placebo (n = 31)	51.8 (14.8)	–9.01 (–13.48, –4.55)
4 weeks	Idebenone (n = 31)	52.8 (12.6)	–1.39 (–6.10, 3.32)	7.63 (1.06, 14.21) p = 0.0236	4.98 (0.65, 9.30) p = 0.0248
	Placebo (n = 31)	51.7 (14.6)	–9.03 (–13.61, –4.44)

1: data is mean (SD);

2: data is estimated mean from MMRM (95% CI);

3: for the treatment difference overall, all post-baseline values were included in the model.